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Background and aim: Amyloidosis refers to a variety of conditions in which amyloid proteins are
abnormally deposited in organs and/or tissues. Amyloidosis is a rare occurrence in thyroid gland.
Methods: A systematic review of the published data on amyloid goiter was carried out by searching
Medline and other online databases (such as Scopus and Endnote) for the period from 1951 to March
2008. A total of 127 publications (case series, single case reports and reviews) was found, of which 31
were case series published from February 1995 to March 2008. Six articles have been considered for our
review because they regard amyloid goiter as a manifestation of both primary and secondary amyloidosis
(a total of 30 cases have been analyzed). Exclusion criterion was the presence of primary thyroid cancer.
Results: The preoperative diagnosis of amyloid goiter should be considered in patients with known
systemic amyloidosis or with a long-standing predisposing disease who present a rapidly growing
thyroid volume in association with a euthyroid state. Fine-needle aspiration biopsy can be performed to
exclude primary malignant lesions of thyroid gland and immunohistochemical studies can identify and
characterize the amyloid deposits.
Conclusion: Amyloid goiter has to be suspected in all patients with a progressive, rapidly growing,
bilateral thyroid enlargement and a concomitant history of chronic inﬂammatory processes. Moreover,
this should be suspected in patients who are known to have disease predisposing to amyloid deposition.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Amyloidgoiter (AG), deﬁnedby thepresenceof amyloidwithin the
thyroid in such quantities as to produce a clinically apparent
enlargement of the gland, is a rare pathologic entity associated with
both primary amyloidosis, a syndrome inwhich there is deposition of
insoluble proteinaceous, amorphous and eosinophilic material in the
exracellularmatrixof someorgans, and secondaryamyloidosis,which
occurs as a result of the accumulation of amyloid A (AA), which is
a portion of the acute-phase serumamyloid A (SAA) proteinproduced
by the liver at times of inﬂammation. In autopsy-based studies intra-
thyroidal amyloid is present in approximately 80% of patients with
secondaryamyloidosis and in 50% of thosewith primaryamyloidosis.1
Amyloidosis can be classiﬁed based on the biochemical nature of
amyloid protein deposits. In primary amyloidosis the major ﬁbrillar
protein is amyloid L (AL), based on the light chain components of
immunoglobulins. In secondary amyloidosis, the ﬁbril subunit is
amyloid A (AA).1
The presence of amyloid in association with thyroid gland
enlargement is also frequently seen in medullary carcinoma of thex: þ39 033 226 0260.
(G. Dionigi).
ciates Ltd. Published by Elsevier Ltthyroid, being identiﬁed in 50–70% of the cases, and in association
with long-standing inﬂammatory disorders such as rheumatoid
arthritis, ankylosing spondylitis, Crohn’s disease and familial
Mediterranean fever (FMF).
Amyloid goiter is a well-established entity that was presented
for the ﬁrst time in 1855 by Rockitansky, who described the ﬁrst
case of amyloid inﬁltration of thyroid gland in patients with
systemic amyloidosis.1 It was in 1858 that Beckmann described the
‘‘condition’’ characterized by clinically detectable thyroid mass
with enlargement of the gland because of amyloid deposition; this
‘‘condition’’ was later named ‘‘amyloid goiter’’ by Eiselberg in 1904.1
Before being coined as a speciﬁc diagnosis, some cases of AG
were reported in the literature, under other names such as
‘‘hamartomatous adiposity with superimposed amyloidosis of
thyroid gland’’ (Fuller RH, Am J Clin Pathol 1950) or ‘‘fatty inﬁltration
in amyloid goiter’’ (Sirsat MV, J Pathol Bacterial 1961). 2
Different authors have written in the literature about systemic
amyloidosis and have reported necropsy cases (e.g. Walker, 1942;
Arean and Klein, 1961; Shapiro, Koluit and Potter, 1971).
2. Methods and results
This review included a total of 30 patients. In detail, ten patients
had disease predisposing to secondary amyloidosis such as chronicd. All rights reserved.
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monia, pulmonary tuberculosis, bronchiectasis, rheumatoid arthritis
and chronic psoriasiform arthritis). Thirteenpatientswere affected by
FMF, a hereditary disease with autosomal recessive inheritance
characterized byacute episodes of fever and serositis of theperitoneal
cavity, pleura and joints, more frequently seen in Mediterranean
countries suchasTurkeyand Israel. FMF isassociatedwithwidespread
deposition of amyloid in tissue, and is indistinguishable from reactive
systemic amyloidosis; the most site involvement seen in amyloidosis
was the kidney. All patients with FMF considered in our study had
a nephrotic syndrome and three of them were renal transplantation
patients with non-functional graft. Moreover, seven patients had
a primary amyloidosis involving the thyroid gland: this is a rare
occurrence and reports in the literature are limited to case reports.
The mean age of patients considered for our review was
43.7 years with ages ranging from 23 to 75 years; 20 weremale and
10 were female.
Amyloid goiter was manifested, in 21 cases, as non-tender
rapidly (over a period of 6 weeks to 1–2 years) enlarging neck
mass; of these six patients had upper airway obstructive symptoms
such as dyspnea, stridor hoarseness and dysphagia.
In the setting of a rapidly enlarging thyroid mass, a malignant
neoplasm of the gland must be excluded. Of particular concern
would be on anaplastic carcinoma or a non-Hodgkin’s malignant
lymphoma, both associated with a rapidly enlarging thyroid mass
and local pressure symptoms. However, in contrast to malignant
thyroid tumors that are often a unilateral disease, AG affects the
thyroid most commonly in a bilateral and diffuse manner.
The remaining nine cases were identiﬁed at autopsy. In the
autopsy cases, in addition to the thyroid the organs invariably
involved by amyloid deposition included the kidney, adrenal, liver
and spleen. Other less common sites of involvement included heart,
pancreas, gastrointestinal tract, lung bone marrow, lymph nodes,
parathyroid gland, salivary glands and testis.
Using physical ﬁndings we categorized each patient’s goiter
based onWorld Health Organization guidelines4 as follows: stage 0,
patients with no goiter; stage IA, patients with goiter palpable but
not visible; stage IB, goiter palpable but visible only when neck fully
extended; stage II, goiter easily visible with neck in normal posi-
tion; stage III, very large goiter.
We classiﬁed the patients of our study as follows: 9 patients in
stage 0 (one diagnosed at autopsy); 6 patients in stage IA; 9 patients
in stage II and the remaining 6 patients in stage III.
Laboratory studies showed euthyroidism in 24 cases; in 4 cases
(all of them affected by FMF) a euthyroid syndrome was docu-
mented (normal TSH level in spite of low value of T3) and 2 cases,
also affected by FMF, showed hyperthyroidism which manifested
with tremors, palpitations and diarrhea.
Ultrasound examination was performed in 14 patients and in all
of themdiffuse enlargement of the thyroid glandwas revealed. Focal
amyloid depositionwas detected as complex or hypoechoic masses;
someof thepatientshadhypoechoicmassesbut inothers the thyroid
gland contained hyperintense areas or had a nodular appearance.
Tc-99m scintigraphic and computed tomographic (CT) studies
werenot performed systematically in all patients. Frequently thoracic
had been performed in those patients with secondary amyloidosis
with chronic obstructing pneumonia and bronchiectasis.
The diagnosis of AG may be facilitated by the use of ultrasound
ﬁne-needle aspiration (FNA) cytology which was performed in 19
patients. Cytological examination of air-dried hematoxylin–eosin
stained smears revealed abundant irregular fragments of pink-
stained amorphous material in 12 cases. The material was more
solid and hyaline-like than colloid in nature. The smears stained
with Congo-red were examined under polarized light, and posi-
tively stained amyloid strands exhibited the characteristic apple-green birefringence; in the remaining cases the FNA cytology
revealed atypical follicular cells. Although helpful in establishing
the presence of amyloid, histochemistry (Congo-red and violet
stains) is less sensitive and speciﬁc than immunohistochemical
evaluation; all types of amyloid stain positively with Congo and
have a similar appearance under polarized light. Potassium
permanganate treatment of Congo red-stained sections may be
helpful in differentiating amyloid A from other types of amyloid.
The deﬁnitive diagnosis of AG restedwith histological evaluation
of resected surgical specimens; surgical treatment was performed
in all patients but one, whowas treated with Dexamethasone. Total
thyroidectomy was performed in 11 patients, subtotal thyroidec-
tomy in 6 patients and in the others the type of surgery was not
speciﬁc. The patient treated with medical therapy manifested the
goiter as the ﬁrst sign of a primary systemic amyloidosis and did not
need surgical treatment because of the decrease in size of the goiter
(from 32.8 to 23.3 ml) after the therapy.
At deﬁnitive histology, the thyroid gland appeared enlarged in
all cases and bilateral involvement was seen in all but one patient.
Thyroid parenchyma was characterized by multiple inhomoge-
neous nodules, varying in diameter from a few millimeters to
several centimeters, and from ﬁrm to soft gelatinous nodules in
consistency, with the presence in some cases of simple cysts and in
others of hemorrhagic ones; the cut surface varied in color from
gray-white to light brown or pale yellow.
In all cases histologic sections stained with hematoxylin–eosin
showed pronounced deposition of an eosinophilic, waxy substance
in the perifollicular site. This substance determined themore or less
complete replacement of the thyroid parenchyma. Vascular
involvement with amyloid was not described in any cases;
however, perivascular deposition was frequently seen.
Also described was the presence in the thyroid parenchyma of
lymphocytic inﬁltrate, foreign-body type giant cells and adipose
tissue, the latter varying in appearance from lobules or clusters of
mature adipocytes replacing the thyroid tissue to focal scattered
adipocytes within the stroma.
3. Discussion
Diffuse enlargement of the thyroid gland secondary to inﬁltration
by amyloid is infrequent, even if involvement of the gland by amyloid
is a relatively common phenomenon. Amyloid goiter can be deﬁned
as thepresenceof amyloidwithin the thyroid gland in suchquantities
as to produce a clinically apparent enlargement of the gland. Focal
microscopicdepositsofamyloid substancemayoftenbe foundwithin
the thyroidgland inassociationwithsystemicamyloidosis,medullary
carcinoma, and less frequently, primary amyloidosis of the thyroid.5,6
The diagnosis of amyloid goiter should be considered in any
patient with systemic amyloidosis and FMF presenting with a bilat-
eral, diffuse goiter associated with a euthyroid state. Usually labo-
ratory studies show normal results for thyroid function tests, even if
in aminority of cases ahypothyroidorhyperthyroid state is detected.
Rarely, amyloid goiter may occur as the ﬁrst sign of systemic
amyloidosis.3,7
Occasionally in AG, the amyloid can also involve the parathyroid
glands, as reported in one of the cases considered for the review.7,8
Many affected patients present symptoms of compression such as
dysphagia, hoarseness or dyspnea. The diagnosis AG must be distin-
guished from themore common types of goiter. FNA biopsy has been
used to aid in the diagnosis of amyloid goiter and to exclude other
differential diagnoses. FNA of the thyroid is a valuable and sensitive
method, and is a safe and easily performed procedure, even if the
deﬁnitive diagnosis of AG is most often made after thyroidectomy.
In conclusion, amyloid goiter should be suspected in all
patients with a progressive, rapidly growing, bilateral thyroid
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processes; a state of euthyroidism can help in the diagnosis. In
many cases ﬁne-needle aspiration biopsy can be performed to
exclude malignant lesions. In order to diagnose amyloid goiter
deﬁnitively thyroidectomy is often necessary. Surgical intervention
is indicated either for aesthetic purposes or to relieve the pressure
symptoms.
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